| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President And CEO | Director
1 company
Lewis Joel serves as a President And CEO at GALT. Across recent SEC filings that breaks down to 5 buys and 12 sells. Those positions are worth an estimated $2.9M at current prices.
Historically, Lewis Joel's trades have earned a middling insider score of 59/100 across 14 rated trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -46.9%.
The biggest single holding is GALT (~$2.9M) as President And CEO. The recent filings there lean toward selling, a net 197,412 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 5, 2019 | GALT Galectin Therapeutics Inc | Director | Buy | 667 | $4.82 | $3,214.07 | +1.0% | |
| Feb 7, 2019 | GALT Galectin Therapeutics Inc | Director | Buy | 1,000 | $4.48 | $4,484.10 | +1.6% | |
| Jan 29, 2019 | GALT Galectin Therapeutics Inc | Director | Buy | 1,000 | $4.81 | $4,805.00 | +1.6% |